Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 48 citing articles:

Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 203
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2193-2227
Open Access | Times Cited: 107
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Matt Shirley
Targeted Oncology (2021) Vol. 17, Iss. 1, pp. 69-84
Open Access | Times Cited: 67
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Shazia Nakhoda, Aldana Vistarop, Y. Lynn Wang
British Journal of Haematology (2022) Vol. 200, Iss. 2, pp. 137-149
Open Access | Times Cited: 60
Radix Puerariae thomsonii polysaccharide (RPP) improves inflammation and lipid peroxidation in alcohol and high-fat diet mice by regulating gut microbiota
Qiong Li, Wenjun Liu, Yulin Feng, et al.
International Journal of Biological Macromolecules (2022) Vol. 209, pp. 858-870
Closed Access | Times Cited: 43
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
Rula Zain, Mauno Vihinen
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 46
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
Skye Montoya, Meghan C. Thompson
Cancers (2023) Vol. 15, Iss. 14, pp. 3648-3648
Open Access | Times Cited: 18
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10374-10374
Open Access | Times Cited: 17
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia
Vera K. Schmid, Elias Hobeika
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Madelyn Burkart, Reem Karmali
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 376-376
Open Access | Times Cited: 20
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Aberrant B-Cell Activation in Systemic Lupus Erythematosus
Na Kang, Xiaohang Liu, Xujie You, et al.
Kidney Diseases (2022) Vol. 8, Iss. 6, pp. 437-445
Open Access | Times Cited: 15
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
Javier Muñoz, Yucai Wang, Preetesh Jain, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 10, pp. 1299-1311
Open Access | Times Cited: 14
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
R Joseph, Thomas E. Wales, Sandrine Jayne, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 2
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain‐of‐function variations
Smith Rjh, Rula Zain
European Journal Of Haematology (2024) Vol. 113, Iss. 1, pp. 130-131
Open Access | Times Cited: 2
The Evolving Role of Bruton’s Tyrosine Kinase Inhibitors in B Cell Lymphomas
Shefali Mehra, M. Gary Nicholls, Justin Taylor
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7516-7516
Open Access | Times Cited: 2
Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship
Lin Wang, Zhengjie Zhang, Dongke Yu, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106577-106577
Closed Access | Times Cited: 6
The TKI Era in Chronic Leukemias
Danilo De Novellis, Fabiana Cacace, Valeria Caprioli, et al.
Pharmaceutics (2021) Vol. 13, Iss. 12, pp. 2201-2201
Open Access | Times Cited: 14
Mannose-decorated ginsenoside Rb1 albumin nanoparticles for targeted anti-inflammatory therapy
Zhihui Fu, Xiao-Hui Wang, Xuan Lu, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 9
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J. Arribas, Sara Napoli, Luciano Cascione, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 3, pp. 368-380
Open Access | Times Cited: 5
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma
Mélody Caillot, Hadjer Miloudi, Antoine Taly, et al.
Molecular Oncology (2023) Vol. 17, Iss. 12, pp. 2546-2564
Open Access | Times Cited: 4
CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies
Brigitte Bauvois, Florence Nguyen‐Khac, Hélène Merle‐Béral, et al.
Biochimie (2024)
Closed Access | Times Cited: 1
The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
Alexandria P. Eiken, Elizabeth Schmitz, Erin M. Drengler, et al.
Hemato (2024) Vol. 5, Iss. 3, pp. 321-340
Open Access | Times Cited: 1
Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID‐19 in chronic lymphocytic leukaemia?
Smith Rjh, Rula Zain, Anders Österborg, et al.
Scandinavian Journal of Immunology (2022) Vol. 95, Iss. 4
Open Access | Times Cited: 7
BTKbase, Bruton Tyrosine Kinase Variant Database in X-Linked Agammaglobulinemia: Looking Back and Ahead
Gerard C. P. Schaafsma, Jouni Väliaho, Qing Wang, et al.
Human Mutation (2023) Vol. 2023, pp. 1-12
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top